What Are Miebo Eye Drops?
Miebo is the first and only prescription eye drop specifically approved to treat dry eye disease by reducing tear evaporation. Manufactured by Bausch + Lomb and FDA-approved in May 2023, it contains a single active ingredient: perfluorohexyloctane ophthalmic solution.
Here’s the thing: most eye drops just add water to the surface of your eye. Miebo does something entirely different. It creates a protective oil-like barrier that stops your existing tears from evaporating. That means it targets the root mechanism of evaporative dry eye, not just the symptom.
Miebo is dispensed by prescription only. Patients must see an ophthalmologist or optometrist to access it. The drop is instilled four times daily and is approved for adults diagnosed with dry eye disease.
What Is Perfluorohexyloctane in Miebo?
Perfluorohexyloctane is a synthetic fluorocarbon compound and the sole active ingredient in Miebo, containing no water, preservatives, steroids, or additives. It forms a single-molecule-thick monolayer across the ocular surface, mimicking the natural meibum oil layer that healthy meibomian glands produce.
Each Miebo drop delivers only 11-14 microliters. Compare that to the 50-60 microliters in standard water-based drops. The reduced volume reflects how efficient the compound is. It needs far less volume to form a complete therapeutic film on your eye.
As a fluorocarbon oil, perfluorohexyloctane is chemically inert. It doesn’t react with ocular tissues. That stability is what supports a long-lasting film that doesn’t irritate the cornea or conjunctiva during normal daily use.
Who Is Miebo Designed For?
Miebo targets adults with dry eye disease caused by meibomian gland dysfunction (MGD), where insufficient natural oils allow tears to evaporate too quickly. MGD disrupts the lipid layer of the tear film, accelerating evaporation and exposing the ocular surface to friction and damage.
Eye care specialists identify three primary candidate groups. First, treatment-naïve patients with high visual demands. Second, patients already undergoing in-office therapies like IPL or radiofrequency. Third, established DED patients still showing rapid tear breakup times despite other treatments.
Contact lens wearers with dry eye are also a key target population. Here’s what that means practically: Miebo requires lens removal before instillation and a 30-minute wait before reinserting lenses. Eye care providers walk patients through this during the prescribing visit.
How Do Miebo Eye Drops Work?
Miebo spreads evenly across the ocular surface after instillation, forming a protective anti-evaporative layer that slows the rate at which tears evaporate from the eye. That barrier function addresses the core deficiency in evaporative dry eye disease.
The perfluorohexyloctane molecule mimics the natural meibum oil that healthy meibomian glands secrete. In patients with MGD, that oil layer is deficient or absent. The tear film is left unprotected against evaporative loss. Miebo substitutes for what’s missing.
Now, here’s the honest part: Bausch + Lomb acknowledges that the exact mechanism isn’t fully understood at the molecular level. But clinical trials confirm measurable effects on corneal staining and dryness symptoms. The ‘how’ is still being studied. The ‘what’ is well documented.
Does Miebo Target Tear Evaporation?
Yes. Miebo is the first prescription treatment specifically designed to address evaporative dry eye by forming a barrier that slows moisture loss from the tear film. No prior approved drug had received FDA clearance for this specific mechanism.
Evaporative dry eye accounts for up to 86% of all dry eye cases. The cause is almost always MGD, where disrupted oil secretion removes the protective lipid cap from the tear film. Tears evaporate rapidly even when the lacrimal gland produces adequate volume.
The protective monolayer Miebo creates lasts up to 6 hours per application. That’s the reason behind the four-times-daily dosing schedule. It also exceeds the typical 1-2 hour relief window from water-based artificial tears, which is a meaningful practical difference.
How Long Does Miebo’s Protective Layer Last?
Miebo’s anti-evaporative monolayer lasts approximately 6 hours per application, aligning with the prescribed four-times-daily dosing regimen. This duration provides consistent ocular surface protection throughout waking hours.
One drop goes in each affected eye, four times daily. Contact lenses must be removed before application and not reinserted for at least 30 minutes. If patients use other eye drops alongside Miebo, spacing applications by at least 5 minutes prevents dilution of the therapeutic layer.
Here’s what most people miss: because Miebo contains no water, patients often can’t feel the drop hit the eye. Clinicians recommend a ‘tap instead of squeeze’ technique on the bottle. This prevents dispensing multiple drops at once, which depletes the supply faster without adding any benefit.
What Are the Ingredients in Miebo?
Miebo contains a single active ingredient, perfluorohexyloctane, with no water, steroids, preservatives, or additional additives in the formulation. That one-ingredient simplicity is a defining feature that distinguishes Miebo from virtually all other ophthalmic solutions on the market.
As a fluorocarbon oil, perfluorohexyloctane is chemically inert and non-reactive with ocular tissues. The compound forms a stable, long-lasting film without the chemical interactions that some multi-ingredient formulations produce on the ocular surface.
The preservative-free nature of Miebo reduces the risk of preservative-related ocular irritation. Benzalkonium chloride, found in many multi-dose eye drops, causes chronic ocular surface inflammation in some patients who use preserved drops over months or years.
Miebo Formulation Overview:
| Property | Miebo | Typical Water-Based Eye Drop |
| Active ingredients | 1 (perfluorohexyloctane) | 1-5+ |
| Preservatives | None | Often present (benzalkonium chloride) |
| Water content | None | Primary ingredient |
| Steroids | None | Varies by product |
| Drop volume | 11-14 microliters | 50-60 microliters |
Is Miebo Preservative-Free?
Yes. Miebo contains no preservatives, a clinically important distinction because preservatives like benzalkonium chloride cause chronic ocular surface inflammation with extended use. This makes Miebo suitable for patients who’ve experienced irritation from preserved drops.
Patients who’ve developed tolerance issues or worsening symptoms from preserved artificial tears are often transitioned to Miebo partly for this reason. The formulation avoids the compounding surface damage that chronic preservative exposure produces over time.
The 3 mL bottle holds approximately 30 days of drops at the prescribed four-times-daily dosage. Some patients report running out sooner due to dispensing difficulties related to the bottle’s small size and the invisible nature of perfluorohexyloctane drops hitting the eye.
What Are the Benefits of Miebo Eye Drops?
Miebo treats both the signs and symptoms of dry eye disease, reducing corneal staining and patient-reported dryness discomfort in phase 3 clinical trials. That dual outcome reflects a comprehensive approach to evaporative DED management.
Continued use of Miebo supports repair of the ocular surface by reducing mechanical friction between the eyelid wiper and the cornea. This friction, known as lid wiper epitheliopathy, causes chronic ocular surface damage in patients with untreated evaporative dry eye.
Patients with high visual demands — extended screen use, reading, contact lens wear — report that Miebo helps maintain visual clarity and comfort throughout the day. The 6-hour barrier duration covers the most demanding portions of typical waking activity.
Key Benefits:
- Reduces corneal staining scores by 2x compared to saline placebo at day 57
- Decreases patient-reported dryness symptoms by approximately 50% at day 57
- Preservative-free formulation avoids chronic preservative-related ocular toxicity
- Single-ingredient formula with no steroids or additives
- Protective layer lasts up to 6 hours per application
Does Miebo Relieve Dry Eye Symptoms?
Yes. Miebo produced an almost 50% decrease in dryness symptoms as measured on the visual analog scale at day 57 in phase 3 clinical trials. The improvement compared against saline placebo reached statistical significance in both pivotal studies.
Miebo targets the gritty, sandy, burning, and irritated sensations of dry eye. These symptoms stem from corneal surface damage caused by inadequate tear film protection. By restoring the lipid barrier, Miebo reduces the surface exposure that generates those sensations throughout the day.
Drugs.com reviewers rate Miebo 7.1 out of 10 from 141 reviews, with 52% reporting positive experiences. Descriptions include ‘liquid silk’ and relief from years of chronic ocular discomfort. That’s consistent with what the clinical trial symptom data shows.
Do Clinical Studies Support Miebo’s Claims?
Yes. Miebo’s phase 3 trials enrolled approximately 1,200 subjects across two studies, making it one of the more rigorously evaluated dry eye treatments to receive FDA approval. Subjects were split equally between Miebo treatment and saline placebo groups.
At day 57, Miebo produced a two-times improvement in total corneal staining scores compared to saline. Corneal staining is an objective clinical marker of ocular surface damage that eye care providers assess using fluorescein dye during examination.
The FDA approved Miebo in May 2023 based on this phase 3 data, designating it the first and only approved prescription treatment targeting tear evaporation. Approval required statistically significant results across both objective and subjective endpoints in both trials.
What Do Miebo Reviews Say?
Miebo holds a 7.1 out of 10 rating on Drugs.com from 141 reviews, with 52% of reviewers reporting positive outcomes and 11% reporting negative experiences. The remaining reviewers fall in the mixed or neutral range, showing real variability in patient response.
Ophthalmologists and optometrists describe Miebo enthusiastically. Several early clinical adopters report that both staff and patients experienced significant improvement within weeks of starting. One ophthalmologist described it as ‘magic’ after prescribing it to multiple patients simultaneously.
The most common positive theme is relief from chronic dry eye after other treatments failed. The most common negative theme is frustration with the bottle design and the high retail cost, particularly for patients without strong insurance coverage.
What Positive Experiences Do Miebo Users Report?
Long-term dry eye sufferers report that Miebo is ‘really the only thing that has significantly helped’ after years of trying multiple treatments without lasting relief from the gritty, sandy sensations of chronic dry eye.
In fact, patients with ocular rosacea-related dry eye describe particular benefit from Miebo. Restasis and artificial tears had offered minimal relief for their condition. Miebo delivered improvement that those options couldn’t.
Multiple users describe the application sensation as ‘like liquid silk on your eye.’ No stinging. No burning. No watery flooding. That’s a contrast from traditional artificial tears, which some patients find unpleasant or startling when instilled.
What Complaints Do Miebo Users Have?
The most common complaint is that the 3 mL bottle does not last 30 days as prescribed, with multiple users reporting the supply running out in 2 weeks or less, creating coverage gaps between refills.
The bottle is also described as extremely hard to squeeze. Because Miebo has no water, patients can’t feel whether the drop hit the eye. That sensory gap leads many to dispense multiple drops per application, depleting the bottle faster than the prescribed single-drop dosage requires.
Without insurance, Miebo costs between $700 and $1,400 per month. The good news? Copay programs can bring that down significantly. But patients without qualifying insurance are often forced to discontinue even after experiencing positive clinical results.
Miebo vs Other Eye Drops: Which Is Better?
Miebo addresses the root cause of evaporative dry eye by blocking moisture loss, while most prescription drops like Restasis and Xiidra target inflammation — these are fundamentally different mechanisms addressing different dry eye subtypes.
Eye care specialists frequently prescribe Miebo alongside anti-inflammatory drops for patients with dry eye that involves both evaporative loss and inflammatory components. The combination addresses multiple contributing pathways simultaneously.
As the first drug approved for evaporative dry eye, Miebo fills a gap that existing prescriptions didn’t address. It doesn’t compete directly with Restasis for the same patient. It serves a distinct therapeutic niche within the broader dry eye treatment landscape.
Prescription Dry Eye Treatment Comparison:
| Feature | Miebo | Restasis | Xiidra |
| Mechanism | Reduces tear evaporation | Reduces inflammation | Reduces inflammation |
| Target dry eye type | Evaporative (MGD) | Inflammatory/aqueous | Inflammatory/aqueous |
| FDA approved | 2023 | 2002 | 2016 |
| Preservative-free | Yes | Yes (emulsion) | Yes |
| Time to results | ~57 days | 3-6 months | 6-12 weeks |
How Does Miebo Compare to Artificial Tears?
Artificial tears add water to dilute and temporarily supplement the tear film, while Miebo creates a physical barrier that prevents the existing tear film from evaporating — a fundamentally different mechanism.
Miebo drops are 11-14 microliters. Artificial tears run 50-60 microliters. The smaller volume delivers a complete therapeutic dose without flooding the eye. And because the perfluorohexyloctane film doesn’t dissolve in water, it doesn’t wash away the way water-based drops do.
Artificial tears typically provide 1-2 hours of relief. Miebo’s monolayer lasts up to 6 hours per application. That duration advantage reduces the frequency of intervention needed throughout the day, which matters for patients managing chronic dry eye.
How Does Miebo Compare to Restasis?
Restasis reduces inflammation in the lacrimal gland to increase natural tear production, while Miebo reduces tear evaporation — these approaches address different dry eye subtypes and are not direct substitutes.
Restasis requires 3-6 months of use before patients typically notice significant improvement. Miebo users in clinical trials showed measurable improvements by day 57. That faster response window is a factor eye care providers weigh when deciding which treatment to initiate first.
Bottom line: clinicians prescribe both simultaneously for complex cases involving evaporative loss and inadequate tear production. The two treatments complement each other. For many patients, the best outcome comes from using both, not choosing between them.
What Are the Side Effects of Miebo?
The most commonly reported Miebo side effects in phase 3 trials were blurred vision and conjunctival redness, each occurring in 1% to 3% of patients who received the treatment. The overall adverse event profile was mild across both pivotal studies.
Some real-world users report a burning sensation lasting up to 30 minutes after instillation, along with a sticky feeling during blinking. These effects aren’t prominently listed in the prescribing information but appear in a subset of patient reviews on WebMD and Drugs.com.
The absence of preservatives in Miebo removes one significant source of long-term ocular toxicity. Benzalkonium chloride is associated with cumulative ocular surface damage when used chronically in preserved eye drops. Miebo doesn’t carry that long-term risk.
Miebo Side Effects Summary:
- Blurred vision (1-3% of clinical trial patients)
- Conjunctival redness (1-3% of clinical trial patients)
- Burning sensation on instillation (reported by some real-world users)
- Sticky feeling during blinking (reported by some real-world users)
Who Should Avoid Miebo?
Miebo should not be instilled while contact lenses are in the eye — patients must remove lenses before each application and wait at least 30 minutes before reinserting them, as Miebo can affect lens wettability.
Clinical trial data for Miebo in pregnant or nursing women is limited. These patients should discuss risks and benefits with their prescribing eye care provider before starting treatment. The safety profile in these populations hasn’t been fully established in controlled studies.
Patients with known hypersensitivity to perfluorohexyloctane should not use Miebo. Any sign of allergic reaction — severe redness, swelling, or worsening irritation — requires immediate discontinuation and prompt medical evaluation by an eye care provider.
Is Miebo FDA Approved?
Yes. The FDA approved Miebo (perfluorohexyloctane ophthalmic solution) in May 2023, granting it status as the first and only prescription eye drop approved for evaporative dry eye. No prior approved drug had received clearance for this specific mechanism of action.
Approval was based on two phase 3 randomized controlled trials demonstrating statistically significant improvements in both corneal staining scores and patient-reported dryness symptoms. The combined trials enrolled approximately 1,200 subjects across both treatment and placebo groups.
The ‘first and only’ designation reflects a genuine regulatory gap Miebo filled. Existing dry eye prescriptions targeted inflammation or tear secretion. Miebo specifically addressed the evaporative lipid barrier deficiency that no prior approved drug had directly treated.
How Much Do Miebo Eye Drops Cost?
Without insurance coverage, Miebo typically costs between $700 and $1,400 per month, making it one of the more expensive prescription eye drops currently available in the United States. This price reflects the novel mechanism and specialty pharmacy distribution model.
Bausch + Lomb offers a copay assistance program through BlinkRx specialty pharmacy, which can significantly reduce out-of-pocket costs for eligible commercially insured patients. Some patients using the program report paying as little as $0-$35 per month.
Insurance coverage for Miebo varies widely by plan. Some insurers require prior authorization or step therapy documentation, meaning patients may need to show they tried other treatments before Miebo is approved for coverage.
Miebo Cost by Coverage Status:
| Coverage Status | Estimated Monthly Cost |
| No insurance | $700 – $1,400 |
| Commercial insurance (with prior authorization) | Varies by plan |
| BlinkRx copay program (eligible patients) | $0 – $35 |
Is Miebo Worth the Price?
For patients who achieve significant relief, Miebo is consistently described as worth the cost despite the high retail price — particularly by those who spent years trying multiple treatments without adequate resolution of chronic dry eye symptoms.
Here’s the harder truth: a segment of reviewers discontinued Miebo not because it stopped working but because they couldn’t sustain the monthly cost. The clinical benefit was real. The financial access wasn’t. That gap is the most common source of dissatisfaction in long-term user reviews.
Eligible patients using BlinkRx copay programs report paying as little as $0-$35 per month. For those with qualifying commercial insurance, that changes the cost-benefit calculation entirely. Checking copay eligibility before dismissing Miebo as too expensive is worth the effort.
Where Can You Buy Miebo?
Miebo requires a valid prescription from an eye care provider and is not available over the counter or without first consulting an ophthalmologist or optometrist. Self-diagnosing and self-treating evaporative dry eye without professional evaluation isn’t recommended.
Bausch + Lomb recommends BlinkRx specialty pharmacy as the preferred dispensing channel. BlinkRx integrates directly with the copay assistance program, streamlining cost reduction for commercially insured patients at the point of dispensing.
Miebo is available at select retail pharmacies for patients without BlinkRx access. Patients should verify availability and insurance processing with their pharmacy before filling the prescription, as not all retail chains stock the product consistently.
How to Get Miebo:
- Schedule an appointment with an ophthalmologist or optometrist.
- Undergo dry eye evaluation including tear breakup time and corneal staining assessment.
- Receive a Miebo prescription if evaporative dry eye is confirmed.
- Fill the prescription via BlinkRx specialty pharmacy for copay assistance.
- Complete the 4-week initial treatment period and schedule a follow-up visit.
Is Miebo Worth It?
Miebo is a clinically validated, FDA-approved treatment that delivers measurable improvement in both objective corneal staining and subjective dryness measures for patients with evaporative dry eye unresolved by other options.
Patients most likely to find Miebo worth it have confirmed MGD-driven evaporative dry eye and haven’t responded adequately to OTC artificial tears or prescription anti-inflammatory drops. The 7.1 out of 10 Drugs.com rating and consistent positive clinician feedback support that profile.
Patients with aqueous-deficient dry eye, limited insurance access, or a preference for water-based drops may find the cost and adjustment period outweigh the benefits. Miebo isn’t a universal dry eye solution. The right candidate profile matters significantly for outcomes.